Biosimilar infliximab versus originator in Crohn’s disease anti-TNF-α naïve and non-naïve patients

INTRODUCTION: Data comparing response to originator and biosimilar infliximab in anti-TNF-α naïve and non-naïve Crohn’s disease patients is limited. AIM: To assess the efficacy, safety, and tolerability of a biosimilar infliximab in comparison to the originator drug in anti-TNF-α naïve and non-naïve...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaniewska, Magdalena, Rosolowski, Mariusz, Moniuszko, Andrzej, Rydzewska, Grazyna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2020
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8456772/
https://www.ncbi.nlm.nih.gov/pubmed/34584581
http://dx.doi.org/10.5114/pg.2020.100750

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8456772/
https://www.ncbi.nlm.nih.gov/pubmed/34584581
http://dx.doi.org/10.5114/pg.2020.100750

Ejemplares similares